Risk Factors of Drug Resistance among Tuberculosis Patients of Prakasam District, Andhra Pradesh, India

Introduction: India is leading in the burden of Tuberculosis (TB) according to the new report of the World Health Organisation (WHO) on the disease. Multi-Drug Resistant TB (MDR-TB) cases have been increasing in India. About half of the world’s MDR-TB cases are present in India. Aim: To assess the incidence of drug resistant TB in Prakasam district, Andhra Pradesh, India, in the second quarter of the year 2019 and to determine the risk factors that are responsible to develop drug resistance to anti-tubercular drugs in the study population. Materials and Methods: A Community based cross-sectional study was conducted from April 1st to June 30th in Prakasam district, Andhra Pradesh. All the registered drug resistant TB cases in Prakasam district who gave consent during the study period were taken as sample. The diagnosed drug resistant TB patients were interviewed and proportions of different variables were calculated and chi-square test was used to test significance of results. Results: Out of 209 TB patients, 88 patients were having drug resistant TB in Prakasam district. Prevalence of Drug resistant TB in Prakasam district was calculated as 5.64 per one lac population. In the second quarter of the year 2019-2020, i.e., from April 1st to June 30th, 88 new cases were identified. Incidence of Drug resistant TB in Prakasam district was calculated as 2.38 per one lac population. Male persons (76%), having the age 20-40 years (42%), 40-60 (38.7%) belonging to middle class (45.5%) and migrating for work (85%) are at more risk of developing drug resistant TB. Most of the patients are developing drug resistant TB directly (70.5%) which is an alarming signal. The rifampicin resistant patients were also developing psychological complications (22). Drug toxicity was observed in 55% of the cases. Conclusion: Incidence of drug resistant TB was more in male persons, above 20 years of age, belonging to middle class socio-economic status and migrating for work. Most of the patients developed drug resistant TB directly without previous history of TB. Drug toxicity was observed in half of the cases. Psychological complications were observed in rifampicin resistant patients. Surveillance activity should be addressed properly to combat the risk factors. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	P SUDHA KUMARI [verfasserIn] M SIVA DURGA PRASAD NAYAK [verfasserIn] USHA DEVI [verfasserIn] SUSMITA [verfasserIn] S SUSHMA [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Schlagwörter:	mycobacterium tuberculosis revised national tuberculosis control programme rifampicin resistance tuberculosis burden

Übergeordnetes Werk:	In: Journal of Clinical and Diagnostic Research - JCDR Research and Publications Private Limited, 2009, 14(2020), 12, Seite LC25-LC30
Übergeordnetes Werk:	volume:14 ; year:2020 ; number:12 ; pages:LC25-LC30

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.7860/JCDR/2020/45508.14386

Katalog-ID:	DOAJ06279616X

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ06279616X
003	DE-627
005	20230503005043.0
007	cr uuu---uuuuu
008	230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.7860/JCDR/2020/45508.14386 \|2 doi
035			\|a (DE-627)DOAJ06279616X
035			\|a (DE-599)DOAJe11e6a03d4eb441b86d70a96b60640f0
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	0		\|a P SUDHA KUMARI \|e verfasserin \|4 aut
245	1	0	\|a Risk Factors of Drug Resistance among Tuberculosis Patients of Prakasam District, Andhra Pradesh, India
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Introduction: India is leading in the burden of Tuberculosis (TB) according to the new report of the World Health Organisation (WHO) on the disease. Multi-Drug Resistant TB (MDR-TB) cases have been increasing in India. About half of the world’s MDR-TB cases are present in India. Aim: To assess the incidence of drug resistant TB in Prakasam district, Andhra Pradesh, India, in the second quarter of the year 2019 and to determine the risk factors that are responsible to develop drug resistance to anti-tubercular drugs in the study population. Materials and Methods: A Community based cross-sectional study was conducted from April 1st to June 30th in Prakasam district, Andhra Pradesh. All the registered drug resistant TB cases in Prakasam district who gave consent during the study period were taken as sample. The diagnosed drug resistant TB patients were interviewed and proportions of different variables were calculated and chi-square test was used to test significance of results. Results: Out of 209 TB patients, 88 patients were having drug resistant TB in Prakasam district. Prevalence of Drug resistant TB in Prakasam district was calculated as 5.64 per one lac population. In the second quarter of the year 2019-2020, i.e., from April 1st to June 30th, 88 new cases were identified. Incidence of Drug resistant TB in Prakasam district was calculated as 2.38 per one lac population. Male persons (76%), having the age 20-40 years (42%), 40-60 (38.7%) belonging to middle class (45.5%) and migrating for work (85%) are at more risk of developing drug resistant TB. Most of the patients are developing drug resistant TB directly (70.5%) which is an alarming signal. The rifampicin resistant patients were also developing psychological complications (22). Drug toxicity was observed in 55% of the cases. Conclusion: Incidence of drug resistant TB was more in male persons, above 20 years of age, belonging to middle class socio-economic status and migrating for work. Most of the patients developed drug resistant TB directly without previous history of TB. Drug toxicity was observed in half of the cases. Psychological complications were observed in rifampicin resistant patients. Surveillance activity should be addressed properly to combat the risk factors.
650		4	\|a mycobacterium tuberculosis
650		4	\|a revised national tuberculosis control programme
650		4	\|a rifampicin resistance
650		4	\|a tuberculosis burden
653		0	\|a Medicine
653		0	\|a R
700	0		\|a M SIVA DURGA PRASAD NAYAK \|e verfasserin \|4 aut
700	0		\|a USHA DEVI \|e verfasserin \|4 aut
700	0		\|a SUSMITA \|e verfasserin \|4 aut
700	0		\|a S SUSHMA \|e verfasserin \|4 aut
773	0	8	\|i In \|t Journal of Clinical and Diagnostic Research \|d JCDR Research and Publications Private Limited, 2009 \|g 14(2020), 12, Seite LC25-LC30 \|w (DE-627)789478048 \|w (DE-600)2775283-5 \|x 0973709X \|7 nnns
773	1	8	\|g volume:14 \|g year:2020 \|g number:12 \|g pages:LC25-LC30
856	4	0	\|u https://doi.org/10.7860/JCDR/2020/45508.14386 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/e11e6a03d4eb441b86d70a96b60640f0 \|z kostenfrei
856	4	0	\|u https://jcdr.net/articles/PDF/14386/45508_CE(Ra1)_P(AK)_PF1(ShG_SL)_PN(SL).pdf \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2249-782X \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/0973-709X \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 14 \|j 2020 \|e 12 \|h LC25-LC30

Indexfelder

author_variant	p s k psk m s d p n msdpn u d ud s s s ss
matchkey_str	article:0973709X:2020----::ikatrodurssacaogueclssainsfrksmit
hierarchy_sort_str	2020
publishDate	2020
allfields	10.7860/JCDR/2020/45508.14386 doi (DE-627)DOAJ06279616X (DE-599)DOAJe11e6a03d4eb441b86d70a96b60640f0 DE-627 ger DE-627 rakwb eng P SUDHA KUMARI verfasserin aut Risk Factors of Drug Resistance among Tuberculosis Patients of Prakasam District, Andhra Pradesh, India 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: India is leading in the burden of Tuberculosis (TB) according to the new report of the World Health Organisation (WHO) on the disease. Multi-Drug Resistant TB (MDR-TB) cases have been increasing in India. About half of the world’s MDR-TB cases are present in India. Aim: To assess the incidence of drug resistant TB in Prakasam district, Andhra Pradesh, India, in the second quarter of the year 2019 and to determine the risk factors that are responsible to develop drug resistance to anti-tubercular drugs in the study population. Materials and Methods: A Community based cross-sectional study was conducted from April 1st to June 30th in Prakasam district, Andhra Pradesh. All the registered drug resistant TB cases in Prakasam district who gave consent during the study period were taken as sample. The diagnosed drug resistant TB patients were interviewed and proportions of different variables were calculated and chi-square test was used to test significance of results. Results: Out of 209 TB patients, 88 patients were having drug resistant TB in Prakasam district. Prevalence of Drug resistant TB in Prakasam district was calculated as 5.64 per one lac population. In the second quarter of the year 2019-2020, i.e., from April 1st to June 30th, 88 new cases were identified. Incidence of Drug resistant TB in Prakasam district was calculated as 2.38 per one lac population. Male persons (76%), having the age 20-40 years (42%), 40-60 (38.7%) belonging to middle class (45.5%) and migrating for work (85%) are at more risk of developing drug resistant TB. Most of the patients are developing drug resistant TB directly (70.5%) which is an alarming signal. The rifampicin resistant patients were also developing psychological complications (22). Drug toxicity was observed in 55% of the cases. Conclusion: Incidence of drug resistant TB was more in male persons, above 20 years of age, belonging to middle class socio-economic status and migrating for work. Most of the patients developed drug resistant TB directly without previous history of TB. Drug toxicity was observed in half of the cases. Psychological complications were observed in rifampicin resistant patients. Surveillance activity should be addressed properly to combat the risk factors. mycobacterium tuberculosis revised national tuberculosis control programme rifampicin resistance tuberculosis burden Medicine R M SIVA DURGA PRASAD NAYAK verfasserin aut USHA DEVI verfasserin aut SUSMITA verfasserin aut S SUSHMA verfasserin aut In Journal of Clinical and Diagnostic Research JCDR Research and Publications Private Limited, 2009 14(2020), 12, Seite LC25-LC30 (DE-627)789478048 (DE-600)2775283-5 0973709X nnns volume:14 year:2020 number:12 pages:LC25-LC30 https://doi.org/10.7860/JCDR/2020/45508.14386 kostenfrei https://doaj.org/article/e11e6a03d4eb441b86d70a96b60640f0 kostenfrei https://jcdr.net/articles/PDF/14386/45508_CE(Ra1)_P(AK)_PF1(ShG_SL)_PN(SL).pdf kostenfrei https://doaj.org/toc/2249-782X Journal toc kostenfrei https://doaj.org/toc/0973-709X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2020 12 LC25-LC30
spelling	10.7860/JCDR/2020/45508.14386 doi (DE-627)DOAJ06279616X (DE-599)DOAJe11e6a03d4eb441b86d70a96b60640f0 DE-627 ger DE-627 rakwb eng P SUDHA KUMARI verfasserin aut Risk Factors of Drug Resistance among Tuberculosis Patients of Prakasam District, Andhra Pradesh, India 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: India is leading in the burden of Tuberculosis (TB) according to the new report of the World Health Organisation (WHO) on the disease. Multi-Drug Resistant TB (MDR-TB) cases have been increasing in India. About half of the world’s MDR-TB cases are present in India. Aim: To assess the incidence of drug resistant TB in Prakasam district, Andhra Pradesh, India, in the second quarter of the year 2019 and to determine the risk factors that are responsible to develop drug resistance to anti-tubercular drugs in the study population. Materials and Methods: A Community based cross-sectional study was conducted from April 1st to June 30th in Prakasam district, Andhra Pradesh. All the registered drug resistant TB cases in Prakasam district who gave consent during the study period were taken as sample. The diagnosed drug resistant TB patients were interviewed and proportions of different variables were calculated and chi-square test was used to test significance of results. Results: Out of 209 TB patients, 88 patients were having drug resistant TB in Prakasam district. Prevalence of Drug resistant TB in Prakasam district was calculated as 5.64 per one lac population. In the second quarter of the year 2019-2020, i.e., from April 1st to June 30th, 88 new cases were identified. Incidence of Drug resistant TB in Prakasam district was calculated as 2.38 per one lac population. Male persons (76%), having the age 20-40 years (42%), 40-60 (38.7%) belonging to middle class (45.5%) and migrating for work (85%) are at more risk of developing drug resistant TB. Most of the patients are developing drug resistant TB directly (70.5%) which is an alarming signal. The rifampicin resistant patients were also developing psychological complications (22). Drug toxicity was observed in 55% of the cases. Conclusion: Incidence of drug resistant TB was more in male persons, above 20 years of age, belonging to middle class socio-economic status and migrating for work. Most of the patients developed drug resistant TB directly without previous history of TB. Drug toxicity was observed in half of the cases. Psychological complications were observed in rifampicin resistant patients. Surveillance activity should be addressed properly to combat the risk factors. mycobacterium tuberculosis revised national tuberculosis control programme rifampicin resistance tuberculosis burden Medicine R M SIVA DURGA PRASAD NAYAK verfasserin aut USHA DEVI verfasserin aut SUSMITA verfasserin aut S SUSHMA verfasserin aut In Journal of Clinical and Diagnostic Research JCDR Research and Publications Private Limited, 2009 14(2020), 12, Seite LC25-LC30 (DE-627)789478048 (DE-600)2775283-5 0973709X nnns volume:14 year:2020 number:12 pages:LC25-LC30 https://doi.org/10.7860/JCDR/2020/45508.14386 kostenfrei https://doaj.org/article/e11e6a03d4eb441b86d70a96b60640f0 kostenfrei https://jcdr.net/articles/PDF/14386/45508_CE(Ra1)_P(AK)_PF1(ShG_SL)_PN(SL).pdf kostenfrei https://doaj.org/toc/2249-782X Journal toc kostenfrei https://doaj.org/toc/0973-709X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2020 12 LC25-LC30
allfields_unstemmed	10.7860/JCDR/2020/45508.14386 doi (DE-627)DOAJ06279616X (DE-599)DOAJe11e6a03d4eb441b86d70a96b60640f0 DE-627 ger DE-627 rakwb eng P SUDHA KUMARI verfasserin aut Risk Factors of Drug Resistance among Tuberculosis Patients of Prakasam District, Andhra Pradesh, India 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: India is leading in the burden of Tuberculosis (TB) according to the new report of the World Health Organisation (WHO) on the disease. Multi-Drug Resistant TB (MDR-TB) cases have been increasing in India. About half of the world’s MDR-TB cases are present in India. Aim: To assess the incidence of drug resistant TB in Prakasam district, Andhra Pradesh, India, in the second quarter of the year 2019 and to determine the risk factors that are responsible to develop drug resistance to anti-tubercular drugs in the study population. Materials and Methods: A Community based cross-sectional study was conducted from April 1st to June 30th in Prakasam district, Andhra Pradesh. All the registered drug resistant TB cases in Prakasam district who gave consent during the study period were taken as sample. The diagnosed drug resistant TB patients were interviewed and proportions of different variables were calculated and chi-square test was used to test significance of results. Results: Out of 209 TB patients, 88 patients were having drug resistant TB in Prakasam district. Prevalence of Drug resistant TB in Prakasam district was calculated as 5.64 per one lac population. In the second quarter of the year 2019-2020, i.e., from April 1st to June 30th, 88 new cases were identified. Incidence of Drug resistant TB in Prakasam district was calculated as 2.38 per one lac population. Male persons (76%), having the age 20-40 years (42%), 40-60 (38.7%) belonging to middle class (45.5%) and migrating for work (85%) are at more risk of developing drug resistant TB. Most of the patients are developing drug resistant TB directly (70.5%) which is an alarming signal. The rifampicin resistant patients were also developing psychological complications (22). Drug toxicity was observed in 55% of the cases. Conclusion: Incidence of drug resistant TB was more in male persons, above 20 years of age, belonging to middle class socio-economic status and migrating for work. Most of the patients developed drug resistant TB directly without previous history of TB. Drug toxicity was observed in half of the cases. Psychological complications were observed in rifampicin resistant patients. Surveillance activity should be addressed properly to combat the risk factors. mycobacterium tuberculosis revised national tuberculosis control programme rifampicin resistance tuberculosis burden Medicine R M SIVA DURGA PRASAD NAYAK verfasserin aut USHA DEVI verfasserin aut SUSMITA verfasserin aut S SUSHMA verfasserin aut In Journal of Clinical and Diagnostic Research JCDR Research and Publications Private Limited, 2009 14(2020), 12, Seite LC25-LC30 (DE-627)789478048 (DE-600)2775283-5 0973709X nnns volume:14 year:2020 number:12 pages:LC25-LC30 https://doi.org/10.7860/JCDR/2020/45508.14386 kostenfrei https://doaj.org/article/e11e6a03d4eb441b86d70a96b60640f0 kostenfrei https://jcdr.net/articles/PDF/14386/45508_CE(Ra1)_P(AK)_PF1(ShG_SL)_PN(SL).pdf kostenfrei https://doaj.org/toc/2249-782X Journal toc kostenfrei https://doaj.org/toc/0973-709X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2020 12 LC25-LC30
allfieldsGer	10.7860/JCDR/2020/45508.14386 doi (DE-627)DOAJ06279616X (DE-599)DOAJe11e6a03d4eb441b86d70a96b60640f0 DE-627 ger DE-627 rakwb eng P SUDHA KUMARI verfasserin aut Risk Factors of Drug Resistance among Tuberculosis Patients of Prakasam District, Andhra Pradesh, India 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: India is leading in the burden of Tuberculosis (TB) according to the new report of the World Health Organisation (WHO) on the disease. Multi-Drug Resistant TB (MDR-TB) cases have been increasing in India. About half of the world’s MDR-TB cases are present in India. Aim: To assess the incidence of drug resistant TB in Prakasam district, Andhra Pradesh, India, in the second quarter of the year 2019 and to determine the risk factors that are responsible to develop drug resistance to anti-tubercular drugs in the study population. Materials and Methods: A Community based cross-sectional study was conducted from April 1st to June 30th in Prakasam district, Andhra Pradesh. All the registered drug resistant TB cases in Prakasam district who gave consent during the study period were taken as sample. The diagnosed drug resistant TB patients were interviewed and proportions of different variables were calculated and chi-square test was used to test significance of results. Results: Out of 209 TB patients, 88 patients were having drug resistant TB in Prakasam district. Prevalence of Drug resistant TB in Prakasam district was calculated as 5.64 per one lac population. In the second quarter of the year 2019-2020, i.e., from April 1st to June 30th, 88 new cases were identified. Incidence of Drug resistant TB in Prakasam district was calculated as 2.38 per one lac population. Male persons (76%), having the age 20-40 years (42%), 40-60 (38.7%) belonging to middle class (45.5%) and migrating for work (85%) are at more risk of developing drug resistant TB. Most of the patients are developing drug resistant TB directly (70.5%) which is an alarming signal. The rifampicin resistant patients were also developing psychological complications (22). Drug toxicity was observed in 55% of the cases. Conclusion: Incidence of drug resistant TB was more in male persons, above 20 years of age, belonging to middle class socio-economic status and migrating for work. Most of the patients developed drug resistant TB directly without previous history of TB. Drug toxicity was observed in half of the cases. Psychological complications were observed in rifampicin resistant patients. Surveillance activity should be addressed properly to combat the risk factors. mycobacterium tuberculosis revised national tuberculosis control programme rifampicin resistance tuberculosis burden Medicine R M SIVA DURGA PRASAD NAYAK verfasserin aut USHA DEVI verfasserin aut SUSMITA verfasserin aut S SUSHMA verfasserin aut In Journal of Clinical and Diagnostic Research JCDR Research and Publications Private Limited, 2009 14(2020), 12, Seite LC25-LC30 (DE-627)789478048 (DE-600)2775283-5 0973709X nnns volume:14 year:2020 number:12 pages:LC25-LC30 https://doi.org/10.7860/JCDR/2020/45508.14386 kostenfrei https://doaj.org/article/e11e6a03d4eb441b86d70a96b60640f0 kostenfrei https://jcdr.net/articles/PDF/14386/45508_CE(Ra1)_P(AK)_PF1(ShG_SL)_PN(SL).pdf kostenfrei https://doaj.org/toc/2249-782X Journal toc kostenfrei https://doaj.org/toc/0973-709X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2020 12 LC25-LC30
allfieldsSound	10.7860/JCDR/2020/45508.14386 doi (DE-627)DOAJ06279616X (DE-599)DOAJe11e6a03d4eb441b86d70a96b60640f0 DE-627 ger DE-627 rakwb eng P SUDHA KUMARI verfasserin aut Risk Factors of Drug Resistance among Tuberculosis Patients of Prakasam District, Andhra Pradesh, India 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: India is leading in the burden of Tuberculosis (TB) according to the new report of the World Health Organisation (WHO) on the disease. Multi-Drug Resistant TB (MDR-TB) cases have been increasing in India. About half of the world’s MDR-TB cases are present in India. Aim: To assess the incidence of drug resistant TB in Prakasam district, Andhra Pradesh, India, in the second quarter of the year 2019 and to determine the risk factors that are responsible to develop drug resistance to anti-tubercular drugs in the study population. Materials and Methods: A Community based cross-sectional study was conducted from April 1st to June 30th in Prakasam district, Andhra Pradesh. All the registered drug resistant TB cases in Prakasam district who gave consent during the study period were taken as sample. The diagnosed drug resistant TB patients were interviewed and proportions of different variables were calculated and chi-square test was used to test significance of results. Results: Out of 209 TB patients, 88 patients were having drug resistant TB in Prakasam district. Prevalence of Drug resistant TB in Prakasam district was calculated as 5.64 per one lac population. In the second quarter of the year 2019-2020, i.e., from April 1st to June 30th, 88 new cases were identified. Incidence of Drug resistant TB in Prakasam district was calculated as 2.38 per one lac population. Male persons (76%), having the age 20-40 years (42%), 40-60 (38.7%) belonging to middle class (45.5%) and migrating for work (85%) are at more risk of developing drug resistant TB. Most of the patients are developing drug resistant TB directly (70.5%) which is an alarming signal. The rifampicin resistant patients were also developing psychological complications (22). Drug toxicity was observed in 55% of the cases. Conclusion: Incidence of drug resistant TB was more in male persons, above 20 years of age, belonging to middle class socio-economic status and migrating for work. Most of the patients developed drug resistant TB directly without previous history of TB. Drug toxicity was observed in half of the cases. Psychological complications were observed in rifampicin resistant patients. Surveillance activity should be addressed properly to combat the risk factors. mycobacterium tuberculosis revised national tuberculosis control programme rifampicin resistance tuberculosis burden Medicine R M SIVA DURGA PRASAD NAYAK verfasserin aut USHA DEVI verfasserin aut SUSMITA verfasserin aut S SUSHMA verfasserin aut In Journal of Clinical and Diagnostic Research JCDR Research and Publications Private Limited, 2009 14(2020), 12, Seite LC25-LC30 (DE-627)789478048 (DE-600)2775283-5 0973709X nnns volume:14 year:2020 number:12 pages:LC25-LC30 https://doi.org/10.7860/JCDR/2020/45508.14386 kostenfrei https://doaj.org/article/e11e6a03d4eb441b86d70a96b60640f0 kostenfrei https://jcdr.net/articles/PDF/14386/45508_CE(Ra1)_P(AK)_PF1(ShG_SL)_PN(SL).pdf kostenfrei https://doaj.org/toc/2249-782X Journal toc kostenfrei https://doaj.org/toc/0973-709X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2020 12 LC25-LC30
language	English
source	In Journal of Clinical and Diagnostic Research 14(2020), 12, Seite LC25-LC30 volume:14 year:2020 number:12 pages:LC25-LC30
sourceStr	In Journal of Clinical and Diagnostic Research 14(2020), 12, Seite LC25-LC30 volume:14 year:2020 number:12 pages:LC25-LC30
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	mycobacterium tuberculosis revised national tuberculosis control programme rifampicin resistance tuberculosis burden Medicine R
isfreeaccess_bool	true
container_title	Journal of Clinical and Diagnostic Research
authorswithroles_txt_mv	P SUDHA KUMARI @@aut@@ M SIVA DURGA PRASAD NAYAK @@aut@@ USHA DEVI @@aut@@ SUSMITA @@aut@@ S SUSHMA @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	789478048
id	DOAJ06279616X
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ06279616X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503005043.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.7860/JCDR/2020/45508.14386</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ06279616X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe11e6a03d4eb441b86d70a96b60640f0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">P SUDHA KUMARI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Risk Factors of Drug Resistance among Tuberculosis Patients of Prakasam District, Andhra Pradesh, India</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction: India is leading in the burden of Tuberculosis (TB) according to the new report of the World Health Organisation (WHO) on the disease. Multi-Drug Resistant TB (MDR-TB) cases have been increasing in India. About half of the world’s MDR-TB cases are present in India. Aim: To assess the incidence of drug resistant TB in Prakasam district, Andhra Pradesh, India, in the second quarter of the year 2019 and to determine the risk factors that are responsible to develop drug resistance to anti-tubercular drugs in the study population. Materials and Methods: A Community based cross-sectional study was conducted from April 1st to June 30th in Prakasam district, Andhra Pradesh. All the registered drug resistant TB cases in Prakasam district who gave consent during the study period were taken as sample. The diagnosed drug resistant TB patients were interviewed and proportions of different variables were calculated and chi-square test was used to test significance of results. Results: Out of 209 TB patients, 88 patients were having drug resistant TB in Prakasam district. Prevalence of Drug resistant TB in Prakasam district was calculated as 5.64 per one lac population. In the second quarter of the year 2019-2020, i.e., from April 1st to June 30th, 88 new cases were identified. Incidence of Drug resistant TB in Prakasam district was calculated as 2.38 per one lac population. Male persons (76%), having the age 20-40 years (42%), 40-60 (38.7%) belonging to middle class (45.5%) and migrating for work (85%) are at more risk of developing drug resistant TB. Most of the patients are developing drug resistant TB directly (70.5%) which is an alarming signal. The rifampicin resistant patients were also developing psychological complications (22). Drug toxicity was observed in 55% of the cases. Conclusion: Incidence of drug resistant TB was more in male persons, above 20 years of age, belonging to middle class socio-economic status and migrating for work. Most of the patients developed drug resistant TB directly without previous history of TB. Drug toxicity was observed in half of the cases. Psychological complications were observed in rifampicin resistant patients. Surveillance activity should be addressed properly to combat the risk factors.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mycobacterium tuberculosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">revised national tuberculosis control programme</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">rifampicin resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">tuberculosis burden</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M SIVA DURGA PRASAD NAYAK</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">USHA DEVI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">SUSMITA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S SUSHMA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Clinical and Diagnostic Research</subfield><subfield code="d">JCDR Research and Publications Private Limited, 2009</subfield><subfield code="g">14(2020), 12, Seite LC25-LC30</subfield><subfield code="w">(DE-627)789478048</subfield><subfield code="w">(DE-600)2775283-5</subfield><subfield code="x">0973709X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:12</subfield><subfield code="g">pages:LC25-LC30</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.7860/JCDR/2020/45508.14386</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e11e6a03d4eb441b86d70a96b60640f0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://jcdr.net/articles/PDF/14386/45508_CE(Ra1)_P(AK)_PF1(ShG_SL)_PN(SL).pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2249-782X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0973-709X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2020</subfield><subfield code="e">12</subfield><subfield code="h">LC25-LC30</subfield></datafield></record></collection>
author	P SUDHA KUMARI
spellingShingle	P SUDHA KUMARI misc mycobacterium tuberculosis misc revised national tuberculosis control programme misc rifampicin resistance misc tuberculosis burden misc Medicine misc R Risk Factors of Drug Resistance among Tuberculosis Patients of Prakasam District, Andhra Pradesh, India
authorStr	P SUDHA KUMARI
ppnlink_with_tag_str_mv	@@773@@(DE-627)789478048
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut
collection	DOAJ
remote_str	true
illustrated	Not Illustrated
issn	0973709X
topic_title	Risk Factors of Drug Resistance among Tuberculosis Patients of Prakasam District, Andhra Pradesh, India mycobacterium tuberculosis revised national tuberculosis control programme rifampicin resistance tuberculosis burden
topic	misc mycobacterium tuberculosis misc revised national tuberculosis control programme misc rifampicin resistance misc tuberculosis burden misc Medicine misc R
topic_unstemmed	misc mycobacterium tuberculosis misc revised national tuberculosis control programme misc rifampicin resistance misc tuberculosis burden misc Medicine misc R
topic_browse	misc mycobacterium tuberculosis misc revised national tuberculosis control programme misc rifampicin resistance misc tuberculosis burden misc Medicine misc R
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Journal of Clinical and Diagnostic Research
hierarchy_parent_id	789478048
hierarchy_top_title	Journal of Clinical and Diagnostic Research
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)789478048 (DE-600)2775283-5
title	Risk Factors of Drug Resistance among Tuberculosis Patients of Prakasam District, Andhra Pradesh, India
ctrlnum	(DE-627)DOAJ06279616X (DE-599)DOAJe11e6a03d4eb441b86d70a96b60640f0
title_full	Risk Factors of Drug Resistance among Tuberculosis Patients of Prakasam District, Andhra Pradesh, India
author_sort	P SUDHA KUMARI
journal	Journal of Clinical and Diagnostic Research
journalStr	Journal of Clinical and Diagnostic Research
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
author_browse	P SUDHA KUMARI M SIVA DURGA PRASAD NAYAK USHA DEVI SUSMITA S SUSHMA
container_volume	14
format_se	Elektronische Aufsätze
author-letter	P SUDHA KUMARI
doi_str_mv	10.7860/JCDR/2020/45508.14386
author2-role	verfasserin
title_sort	risk factors of drug resistance among tuberculosis patients of prakasam district, andhra pradesh, india
title_auth	Risk Factors of Drug Resistance among Tuberculosis Patients of Prakasam District, Andhra Pradesh, India
abstract	Introduction: India is leading in the burden of Tuberculosis (TB) according to the new report of the World Health Organisation (WHO) on the disease. Multi-Drug Resistant TB (MDR-TB) cases have been increasing in India. About half of the world’s MDR-TB cases are present in India. Aim: To assess the incidence of drug resistant TB in Prakasam district, Andhra Pradesh, India, in the second quarter of the year 2019 and to determine the risk factors that are responsible to develop drug resistance to anti-tubercular drugs in the study population. Materials and Methods: A Community based cross-sectional study was conducted from April 1st to June 30th in Prakasam district, Andhra Pradesh. All the registered drug resistant TB cases in Prakasam district who gave consent during the study period were taken as sample. The diagnosed drug resistant TB patients were interviewed and proportions of different variables were calculated and chi-square test was used to test significance of results. Results: Out of 209 TB patients, 88 patients were having drug resistant TB in Prakasam district. Prevalence of Drug resistant TB in Prakasam district was calculated as 5.64 per one lac population. In the second quarter of the year 2019-2020, i.e., from April 1st to June 30th, 88 new cases were identified. Incidence of Drug resistant TB in Prakasam district was calculated as 2.38 per one lac population. Male persons (76%), having the age 20-40 years (42%), 40-60 (38.7%) belonging to middle class (45.5%) and migrating for work (85%) are at more risk of developing drug resistant TB. Most of the patients are developing drug resistant TB directly (70.5%) which is an alarming signal. The rifampicin resistant patients were also developing psychological complications (22). Drug toxicity was observed in 55% of the cases. Conclusion: Incidence of drug resistant TB was more in male persons, above 20 years of age, belonging to middle class socio-economic status and migrating for work. Most of the patients developed drug resistant TB directly without previous history of TB. Drug toxicity was observed in half of the cases. Psychological complications were observed in rifampicin resistant patients. Surveillance activity should be addressed properly to combat the risk factors.
abstractGer	Introduction: India is leading in the burden of Tuberculosis (TB) according to the new report of the World Health Organisation (WHO) on the disease. Multi-Drug Resistant TB (MDR-TB) cases have been increasing in India. About half of the world’s MDR-TB cases are present in India. Aim: To assess the incidence of drug resistant TB in Prakasam district, Andhra Pradesh, India, in the second quarter of the year 2019 and to determine the risk factors that are responsible to develop drug resistance to anti-tubercular drugs in the study population. Materials and Methods: A Community based cross-sectional study was conducted from April 1st to June 30th in Prakasam district, Andhra Pradesh. All the registered drug resistant TB cases in Prakasam district who gave consent during the study period were taken as sample. The diagnosed drug resistant TB patients were interviewed and proportions of different variables were calculated and chi-square test was used to test significance of results. Results: Out of 209 TB patients, 88 patients were having drug resistant TB in Prakasam district. Prevalence of Drug resistant TB in Prakasam district was calculated as 5.64 per one lac population. In the second quarter of the year 2019-2020, i.e., from April 1st to June 30th, 88 new cases were identified. Incidence of Drug resistant TB in Prakasam district was calculated as 2.38 per one lac population. Male persons (76%), having the age 20-40 years (42%), 40-60 (38.7%) belonging to middle class (45.5%) and migrating for work (85%) are at more risk of developing drug resistant TB. Most of the patients are developing drug resistant TB directly (70.5%) which is an alarming signal. The rifampicin resistant patients were also developing psychological complications (22). Drug toxicity was observed in 55% of the cases. Conclusion: Incidence of drug resistant TB was more in male persons, above 20 years of age, belonging to middle class socio-economic status and migrating for work. Most of the patients developed drug resistant TB directly without previous history of TB. Drug toxicity was observed in half of the cases. Psychological complications were observed in rifampicin resistant patients. Surveillance activity should be addressed properly to combat the risk factors.
abstract_unstemmed	Introduction: India is leading in the burden of Tuberculosis (TB) according to the new report of the World Health Organisation (WHO) on the disease. Multi-Drug Resistant TB (MDR-TB) cases have been increasing in India. About half of the world’s MDR-TB cases are present in India. Aim: To assess the incidence of drug resistant TB in Prakasam district, Andhra Pradesh, India, in the second quarter of the year 2019 and to determine the risk factors that are responsible to develop drug resistance to anti-tubercular drugs in the study population. Materials and Methods: A Community based cross-sectional study was conducted from April 1st to June 30th in Prakasam district, Andhra Pradesh. All the registered drug resistant TB cases in Prakasam district who gave consent during the study period were taken as sample. The diagnosed drug resistant TB patients were interviewed and proportions of different variables were calculated and chi-square test was used to test significance of results. Results: Out of 209 TB patients, 88 patients were having drug resistant TB in Prakasam district. Prevalence of Drug resistant TB in Prakasam district was calculated as 5.64 per one lac population. In the second quarter of the year 2019-2020, i.e., from April 1st to June 30th, 88 new cases were identified. Incidence of Drug resistant TB in Prakasam district was calculated as 2.38 per one lac population. Male persons (76%), having the age 20-40 years (42%), 40-60 (38.7%) belonging to middle class (45.5%) and migrating for work (85%) are at more risk of developing drug resistant TB. Most of the patients are developing drug resistant TB directly (70.5%) which is an alarming signal. The rifampicin resistant patients were also developing psychological complications (22). Drug toxicity was observed in 55% of the cases. Conclusion: Incidence of drug resistant TB was more in male persons, above 20 years of age, belonging to middle class socio-economic status and migrating for work. Most of the patients developed drug resistant TB directly without previous history of TB. Drug toxicity was observed in half of the cases. Psychological complications were observed in rifampicin resistant patients. Surveillance activity should be addressed properly to combat the risk factors.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	12
title_short	Risk Factors of Drug Resistance among Tuberculosis Patients of Prakasam District, Andhra Pradesh, India
url	https://doi.org/10.7860/JCDR/2020/45508.14386 https://doaj.org/article/e11e6a03d4eb441b86d70a96b60640f0 https://jcdr.net/articles/PDF/14386/45508_CE(Ra1)_P(AK)_PF1(ShG_SL)_PN(SL).pdf https://doaj.org/toc/2249-782X https://doaj.org/toc/0973-709X
remote_bool	true
author2	M SIVA DURGA PRASAD NAYAK USHA DEVI SUSMITA S SUSHMA
author2Str	M SIVA DURGA PRASAD NAYAK USHA DEVI SUSMITA S SUSHMA
ppnlink	789478048
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.7860/JCDR/2020/45508.14386
up_date	2024-07-03T14:05:32.642Z
_version_	1803567007157714944
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ06279616X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503005043.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.7860/JCDR/2020/45508.14386</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ06279616X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe11e6a03d4eb441b86d70a96b60640f0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">P SUDHA KUMARI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Risk Factors of Drug Resistance among Tuberculosis Patients of Prakasam District, Andhra Pradesh, India</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction: India is leading in the burden of Tuberculosis (TB) according to the new report of the World Health Organisation (WHO) on the disease. Multi-Drug Resistant TB (MDR-TB) cases have been increasing in India. About half of the world’s MDR-TB cases are present in India. Aim: To assess the incidence of drug resistant TB in Prakasam district, Andhra Pradesh, India, in the second quarter of the year 2019 and to determine the risk factors that are responsible to develop drug resistance to anti-tubercular drugs in the study population. Materials and Methods: A Community based cross-sectional study was conducted from April 1st to June 30th in Prakasam district, Andhra Pradesh. All the registered drug resistant TB cases in Prakasam district who gave consent during the study period were taken as sample. The diagnosed drug resistant TB patients were interviewed and proportions of different variables were calculated and chi-square test was used to test significance of results. Results: Out of 209 TB patients, 88 patients were having drug resistant TB in Prakasam district. Prevalence of Drug resistant TB in Prakasam district was calculated as 5.64 per one lac population. In the second quarter of the year 2019-2020, i.e., from April 1st to June 30th, 88 new cases were identified. Incidence of Drug resistant TB in Prakasam district was calculated as 2.38 per one lac population. Male persons (76%), having the age 20-40 years (42%), 40-60 (38.7%) belonging to middle class (45.5%) and migrating for work (85%) are at more risk of developing drug resistant TB. Most of the patients are developing drug resistant TB directly (70.5%) which is an alarming signal. The rifampicin resistant patients were also developing psychological complications (22). Drug toxicity was observed in 55% of the cases. Conclusion: Incidence of drug resistant TB was more in male persons, above 20 years of age, belonging to middle class socio-economic status and migrating for work. Most of the patients developed drug resistant TB directly without previous history of TB. Drug toxicity was observed in half of the cases. Psychological complications were observed in rifampicin resistant patients. Surveillance activity should be addressed properly to combat the risk factors.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mycobacterium tuberculosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">revised national tuberculosis control programme</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">rifampicin resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">tuberculosis burden</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M SIVA DURGA PRASAD NAYAK</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">USHA DEVI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">SUSMITA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S SUSHMA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Clinical and Diagnostic Research</subfield><subfield code="d">JCDR Research and Publications Private Limited, 2009</subfield><subfield code="g">14(2020), 12, Seite LC25-LC30</subfield><subfield code="w">(DE-627)789478048</subfield><subfield code="w">(DE-600)2775283-5</subfield><subfield code="x">0973709X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:12</subfield><subfield code="g">pages:LC25-LC30</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.7860/JCDR/2020/45508.14386</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e11e6a03d4eb441b86d70a96b60640f0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://jcdr.net/articles/PDF/14386/45508_CE(Ra1)_P(AK)_PF1(ShG_SL)_PN(SL).pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2249-782X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0973-709X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2020</subfield><subfield code="e">12</subfield><subfield code="h">LC25-LC30</subfield></datafield></record></collection>
score	7.4009047

Nicht das Richtige dabei?

Schreiben Sie uns!

Risk Factors of Drug Resistance among Tuberculosis Patients of Prakasam District, Andhra Pradesh, India

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?